The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: Estimates using the Archimedes Model

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 337-347

  van Herick, Andrew ^a   Andy Schuetz, C ^a   Alperin, Peter ^a   Bullano, Michael F ^b   Balu, Sanjeev ^b   Gandhi, Sanjay ^b  

^a Archimedes Inc   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Atorvastatin; Modeling; Rosuvastatin; Simulation; Simvastatin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; ARCHIMEDES MODEL; ARTICLE; CALIBRATION; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DISEASE MARKER; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACY; SIMULATION; STATISTICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

EID: 84869161699     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s35487     Document Type: Article

References (25)

1. Mackay J, Mensah GA. The Atlas Of Heart Disease And Stroke. Geneva: World Health Organization; 2004. Available from: http://www.who.int/cardiovascular_diseases/resources/atlas/en/. Accessed January 20, 2012.
2. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227-239.
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
4. Willey VJ, Bullano MF, Shoetan NN, Gandhi SK. Therapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatin. Curr Med Res Opin. 2010;26(1):121-128.
5. Waters DD, Brotons C, Chiang CW, et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation. 2009;120(1):28-34.
6. Eddy DM, Schlessinger L. Validation of the archimedes diabetes model. Diabetes Care. 2003;26(11):3102-3110.
7. Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care. 2003;26(11):3093-3101.
8. National Health and Nutrition Examination Survey data 1999-2006 [webpage on the Internet]. Atlanta, GA: Centers for Disease Control and Prevention [updated June 19, 2012]. Available from: http://www.cdc.gov/nchs/nhanes.htm. Accessed January 20, 2012.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
11. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-2445.
12. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
13. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
14. Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform. 2002;35(1):37-50.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
16. United States Department of Health and Human Services. JNC 7 Express: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health; 2003.
17. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31(1):173-175.
18. Schuetz CA, van Herick A, Alperin P, Peskin B, Hsia J, Gandhi S. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes Model. J Med Econ. June 20, 2012. [Epub ahead of print.]
19. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-160.
20. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319(7223):1492-1495.
21. Jones PH. Statins: the case for higher, individualized starting doses. Cleve Clin J Med. 2005;72(9):811-816.
22. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-1504.
23. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
24. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
25. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.